RGT RGT
Company Profile ↓Company Overview
RGT (RGT) is a publicly traded company listed on with a market capitalization of $93.98M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 87.8%, reflecting efficient use of shareholder capital.
Trades at an undemanding P/E of 10.6.
Maintains a net profit margin of 99.0%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $88.69M (+805.0% YoY); net profit $87.76M.
- Trailing 12 Months Year-on-year growth — revenue +805.0%, earnings +929.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 805.00% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 929.04% |
Stock Price Performance
| 1 Year: | +12.41% |
| 6 Months: | -1.17% |
| 3 Months: | -3.31% |
| 1 Month: | -1.24% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)47.39 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 87.8%.
- Excellent profit margin of 99.0%.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | -23.92M | 332.00M | 9.80M | 88.69M |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 339.96K | 2.36M | 1.27M | 930.46K |
| Operating Income | - | - | - | - | - |
| EBITDA | - | - | - | - | - |
| Interest Expense | - | 116.40K | 2.20M | 255.17K | 762.87K |
| Pretax Income | - | -24.26M | 329.64M | 8.53M | 87.76M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -24.26M | 329.64M | 8.53M | 87.76M |
| Diluted EPS | 2.18 | -3.87 | 1.64 | 1.35 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 68.91M | 79.13M | 84.16M | 100.45M |
| Current Assets | - | - | - | - | - |
| Cash & Equivalents | - | 5.37K | 141.65K | 5.48K | 6.61K |
| Inventory | - | - | - | - | - |
| Receivables | - | 159.71K | 520.74K | 1.11M | 320.28K |
| Total Liabilities | - | 4.22M | 4.55M | 2.36M | 432.94K |
| Current Liabilities | - | - | - | - | - |
| Long Term Debt | - | - | - | - | - |
| Total Debt | 4.00M | 4.00M | 4.00M | 2.00M | - |
| Total Equity | - | 64.69M | 74.58M | 81.80M | 100.01M |
| Shares Outstanding | - | 6.31M | 6.36M | 6.52M | 6.56M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 442.53K | 599.26K | 19.60M | 2.67M |
| Investing Cash Flow | - | - | - | - | - |
| Financing Cash Flow | - | -440.37K | -462.99K | -19.66M | -2.67M |
| Capital Expenditure | - | - | - | - | - |
| Free Cash Flow | - | 442.53K | 599.26K | 19.60M | 2.67M |
| Net Change in Cash | - | 2.15K | 136.27K | -57.45K | 1.13K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | 101.4% | 99.3% | 87.0% | 99.0% |
| ROE % | - | -37.5% | 442.0% | 10.4% | 87.7% |
| ROCE % | - | - | - | - | - |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RGT
Royce Global Trust (NYSE: RGT) as of Aug 31, 2026 - TradingView
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxQVzhvZERyeWR1Wkx4LXdSMjk0T05wb21HOWZBbDl0YjZJeFZleFFfSUh2cTBZZXBTekg1aU1QNXhKU3FJdjBBdUQwSzFxYUpkcGljQ1V5NVB6VzNNQ2hESDVqWll4N2o1QXVVbjEzMlJRTklncEV5M3Y4WUo4RXM5OFF0MTVmOXpVcktpOX…
Argent BioPharma (ASX:RGT) Surges 21.43% as the Market Reprices the Stock - Kalkine
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNRmdYRWZvQXJRc0JpNEE2YTR0T0pCVk9XSTd2X2lna0x0Wms1Xzl0QVgtTm5qeDJwYUJuaE05eHlWX0k3MHEzbGxrNUdaT0QyVU0tSWV0UXVFZFc3MkItOWltRlJvMFMxNGZCMTVUZHJmU2NtNnFPbFEzb3o0QWcxdldFV3pTNXFqaWtXeD…
Royce Global Trust (RGT) Slips 0.57% to $14.19, Sitting Midway Between $13.48 Support and $14.90 Resistance - Call Spread Alert - https://www.dars.gov.et/
<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxNZ2xPRzkxTHBidDBwSjJCeUI5bEVyeXdaUjc3UGc0MkRiRk1QdFRwRzFtUzQ0Q2hGbkJYMDM5aFNqWkZIN0Y4QUNMOFg2bC1LcDdOWXoxcjNrSUxkV1RkYjd0NjNLdzhLcXR1c3hnd1E5LUVPVm9ta2pXeHNLb0lZbHdUUGVHeUJqczRjdG…
Liquidity Mapping Around (RGT) Price Events - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxQYnZPYzFWUXdMR3Z2VS1Zd2hUU0lkRmVSbE5aYmF1MDRoVm15eTdBRVJOSEtYeHg2MllZOFI2X00wQmRUWjZwd1k2SjBKRW1CMzIxakwxQzNISmg1WjlTRlVCQkEyQmxmMWZGY0gyQzkxSFA2T2VzSFVydXZvbGVEYUlENnhNSjRaa0llWH…
Argent BioPharma (ASX:RGT): Why This Stock Remains on Investors' Radar - Kalkine
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxOb21GMjJzSUFnZF90dmZTNmlFUy1TdVoxQk0yY3lQN2EwbHdXZHhZRVNSdmRudjczY0RkSUJIeU9ZSWVzRzk0bHBRSVVGaXZ2dFhsMjU2STdYTWEwdXgycThtWm1KUzZWb2FNSFhLRjBJRTFxbnkzbk11Zl9acEIwUzRuWkdkdjdpc0tUcn…
Argent BioPharma Limited (RGT.AX) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiVEFVX3lxTFBGOVg5V0FITnhnQURzTHpFaEp5Z2lxY3Z3dUR0aVo5Z2NzQ1RMX1dNMVZEcS04STVVTVlFeUVRRk4ydW9IUF9JcVE2N3pNOUtCMlI4Nw?oc=5" target="_blank">Argent BioPharma Limited (RGT.AX) Stock Price, News, …
RGT — Frequently Asked Questions
What is the current share price of RGT?
As of 2026-10-23 16:27 PDT, RGT trades at $14.32 on NASDAQ/NYSE. Its 52-week range is $11.86 to $15.58.
What is the market capitalisation of RGT?
RGT has a market capitalisation of $93.98M on NASDAQ/NYSE.
What is the P/E ratio of RGT?
RGT trades at a trailing price-to-earnings (P/E) ratio of 10.61. Its price-to-book (P/B) ratio is 0.94.
What is the return on equity (ROE) of RGT?
RGT has a return on equity (ROE) of 87.75%.
Is RGT a good stock to buy?
This page provides a data-driven analysis of RGT, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.